CI

At a glance

ClinicalIndex Comparison Record
Phase 3Not Yet Recruiting· 7,500 target
Drug / intervention
Colchicine 0.5 mg +1 moredrug
Likely dose
Colchicine 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07035405
NCT07035405Phase 3Not Yet Recruiting
CompareCT.gov

Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX): a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial

Beijing Tiantan Hospital·interventional·Posted Jun 25, 2025·Updated Jun 27, 2025

In Brief

A Phase 3 clinical trial evaluating Colchicine 0.5 mg and Placebo colchicine for Stroke. Not yet recruiting, targeting 7,500 participants.

Detailed Summary

The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
Countries--
CollaboratorsShenzhen Medical Academy of Research and Translation

Timeline

Phase 3Not Yet Recruiting
2026202720282029
First PostedJun 25, 2025
Enrollment StartJul 4, 2025
Primary CompletionDec 31, 2028
TodayJul 1, 2026
Enrollment to primary: 3.5 yearsPosted 1.0 years agoPrimary completion in 2.5 years

Interventions

Colchicine 0.5 mgdrug

Oral colchicine will be initiated with a dose of 0.5 mg per day.

Placebo colchicinedrug

Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.